Key Details
Price
$6.05Last Dividend
$1.50TTM Dividend Yield
24.79%Annual Revenue
$8.27 MAnnual EPS
-$23.35Annual ROE
-4031.44%Beta
1.62Events Calendar
Next earnings date:
Jan 16, 2025Recent quarterly earnings:
Aug 09, 2024Recent annual earnings:
Mar 29, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
July 19, 2024Next split:
N/ARecent split:
June 22, 2023Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with SCNX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
SCNX
globenewswire.com10 December 2024
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), focused on developing and commercializing novel branded, specialty pharma products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent, No. 12,156,869 (the ‘869 patent), further strengthening the intellectual property position and coverage for the Company's SCN-102 product. The ‘869 patent is in addition to the previously granted patent for SCN-102 by the USPTO, No. 11,890,273 (the ‘273 patent).
FAQ
- What is the primary business of Scienture Holdings?
- What is the ticker symbol for Scienture Holdings?
- Does Scienture Holdings pay dividends?
- What sector is Scienture Holdings in?
- What industry is Scienture Holdings in?
- What country is Scienture Holdings based in?
- When did Scienture Holdings go public?
- Is Scienture Holdings in the S&P 500?
- Is Scienture Holdings in the NASDAQ 100?
- Is Scienture Holdings in the Dow Jones?
- When was Scienture Holdings's last earnings report?
- When does Scienture Holdings report earnings?
- Should I buy Scienture Holdings stock now?
What is the primary business of Scienture Holdings?
Scienture Holdings is a biotechnology company focused on developing innovative therapies and solutions for various medical conditions, aiming to improve patient outcomes through advanced scientific research and technology.
What is the ticker symbol for Scienture Holdings?
The ticker symbol for Scienture Holdings is NASDAQ:SCNX
Does Scienture Holdings pay dividends?
Yes, Scienture Holdings pays dividends. The last payment was $1.50, with an ex-dividend date on 19 July 2024
What sector is Scienture Holdings in?
Scienture Holdings is in the Healthcare sector
What industry is Scienture Holdings in?
Scienture Holdings is in the Pharmaceutical Retailers industry
What country is Scienture Holdings based in?
Scienture Holdings is headquartered in United States
When did Scienture Holdings go public?
Scienture Holdings's initial public offering (IPO) was on 06 February 2014
Is Scienture Holdings in the S&P 500?
No, Scienture Holdings is not included in the S&P 500 index
Is Scienture Holdings in the NASDAQ 100?
No, Scienture Holdings is not included in the NASDAQ 100 index
Is Scienture Holdings in the Dow Jones?
No, Scienture Holdings is not included in the Dow Jones index
When was Scienture Holdings's last earnings report?
Scienture Holdings's most recent earnings report was on 9 August 2024
When does Scienture Holdings report earnings?
The next expected earnings date for Scienture Holdings is 16 January 2025
Should I buy Scienture Holdings stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions